The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Abstract
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is a key strategy in treating hypertension and cardiovascular and renal diseases. However, RAAS inhibitors (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, and direct renin inhibitors) increase the risk of hyperkalemia (serum potassium >5.5 mmol/L). This review evaluates the effects on serum potassium levels of RAAS inhibitors. Using PubMed, we searched for clinical trials published up to December 2008 assessing the effects on serum potassium levels of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, and direct renin inhibitors, alone and in combination, in patients with hypertension, heart failure (HF), or chronic kidney disease (CKD); 39 studies were identified. In patients with hypertension without risk factors for hyperkalemia, the incidence of hyperkalemia with RAAS inhibitor monotherapy is low (< or =2%), whereas rates are higher with dual RAAS inhibition ( approximately 5%). The incidence of hyperkalemia is also increased in patients with HF or CKD (5% to 10%). However, increases in serum potassium levels are small ( approximately 0.1 to 0.3 mmol/L), and rates of study discontinuation due to hyperkalemia are low, even in high-risk patient groups (1% to 5%). Patients with HF or CKD are at greater risk of hyperkalemia with RAAS inhibitors than those without these conditions. However, the absolute changes in serum potassium are generally small and unlikely to be clinically significant. Moreover, these patients are likely to derive benefit from RAAS inhibition. Rather than denying them an effective treatment, electrolyte levels should be closely monitored in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
McMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710 · cited 1×
“(25) in patients with nondiabetic CKD (proteinuria 300 mg/d) showed that in those with baseline serum creatinine 3.”
BackgroundMcKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Oparil, S., Yarows, S. A., Patel, S., Fang, H., Zhang, J., & Satlin, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61124-6 · Cited by 444
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
McMurray, J. J. V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J., Verma, A., & Lewsey, J. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.107.740704 · Cited by 358
Influence of hemolysis on routine clinical chemistry testing
Lippi, G., Luca Salvagno, G., Montagnana, M., Brocco, G., & Cesare Guidi, G. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.054 · Cited by 344
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 338
Acker, C. G., Johnson, J. P., Palevsky, P. M., & Greenberg, A. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.8.917 · Cited by 327
Renal complications of nonsteroidal anti-inflammatory drugs
Schlondorff, D. (1993) · Kidney International · doi:10.1038/ki.1993.293 · Cited by 279
Goldberg, A. I., Dunlay, M. C., & Sweet, C. S. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80413-5 · Cited by 270
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
Bakris, G. L., Siomos, M., Richardson, D., Janssen, I., Bolton, W. K., Hebert, L., Agarwal, R., & Catanzaro, D. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00381.x · Cited by 248
MacKinnon, M., Shurraw, S., Akbari, A., Knoll, G. A., Jaffey, J., & Clark, H. D. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.077 · Cited by 246
Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L., & Mukherjee, R. (2008) · Circulation · doi:10.1161/circulationaha.108.778811 · Cited by 235
Reardon, L. C., & Macpherson, D. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.26 · Cited by 222
Hemolyzed Specimens: A Reason for Rejection or a Clinical Challenge?
Carraro, P., Servidio, G., & Plebani, M. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.2.306 · Cited by 218
Chrysostomou, A., Pedagogos, E., MacGregor, L., & Becker, G. J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01040905 · Cited by 211
Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients
Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., & Fakouhi, K. (2002) · Hypertension · doi:10.1161/01.hyp.0000025146.19104.fe · Cited by 210
Uresin, Y., Taylor, A. A., Kilo, C., Tschöpe, D., Santonastaso, M., Ibram, G., Fang, H., & Satlin, A. (2007) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2007.028 · Cited by 210
Baruch, L., Anand, I., Cohen, I. S., Ziesche, S., Judd, D., & Cohn, J. N. (1999) · Circulation · doi:10.1161/01.cir.99.20.2658 · Cited by 202
van den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., & Krumholz, H. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.18.1930 · Cited by 184
Hyperkalemia in Dialysis Patients
Ahmed, J., & Weisberg, L. S. (2001) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2001.00087.x · Cited by 178
Incidence and Predictors of Hyperkalemia in Patients With Heart Failure
Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.067 · Cited by 170 · cited 1×
“Importantly, post hoc analyses of the CHARM-Added and EPHESUS studies have shown that the benefits of dual RAAS inhibition for cardiovascular morbidity and mortality over a single RAAS inhibitor are maintained in the subgroups of patients at the highest risk of developing hyperkalemia, such as those with CKD (24,39,54…”
MethodPharmacotherapy for Heart Failure in Patients with Renal Insufficiency
Shlipak, M. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-11-200306030-00013 · Cited by 169
Shah, K. B., Rao, K., Sawyer, R., & Gottlieb, S. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.010 · Cited by 143
Distinguishing the Antihypertensive and Electrolyte Effects of Eplerenone
Levy, D. G., Rocha, R., & Funder, J. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032149 · Cited by 133
Cruickshank, J. K., Mbanya, J. C., Wilks, R., Balkau, B., Forrester, T., Anderson, S. G., Mennen, L. I., Forhan, A., Riste, L., & McFarlane‐Anderson, N. (2001) · Journal of Hypertension · doi:10.1097/00004872-200101000-00006 · Cited by 128
Hyperkalemia as a Complication of Drug Therapy
Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370050063011 · Cited by 128
Jennings, D. L., Kalus, J. S., Coleman, C. I., Manierski, C., & Yee, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02097.x · Cited by 124
McGill, J. B., & Reilly, P. A. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80072-2 · Cited by 118
White, W. B., Carr, A. A., Krause, S. L., Jordan, R., Roniker, B., & Oigman, W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00461-2 · Cited by 109
Weir, M. R., Bush, C. A., Anderson, D. R., Zhang, J. Y., Keefe, D. L., & Satlin, A. (2007) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.04.004 · Cited by 109
Self-citationFurumatsu, Y., Nagasawa, Y., Tomida, K., Mikami, S., KANEKO, T., Okada, N., Tsubakihara, Y., Imai, E., & SHOJI, T. (2008) · Hypertension Research · doi:10.1291/hypres.31.59 · Cited by 107
Immunosuppressant-Induced Nephropathy
Olyaei, A. J., de Mattos, A. M., & Bennett, W. M. (1999) · Drug Safety · doi:10.2165/00002018-199921060-00004 · Cited by 106
Tylicki, L., Rutkowski, P., Renke, M., Larczyński, W., Aleksandrowicz, E., Łysiak−Szydłowska, W., & Rutkowski, B. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.297 · Cited by 104
Raebel, M. A., McClure, D. L., Simon, S. R., Chan, K. A., Feldstein, A. C., Andrade, S. E., Lafata, J. E., Roblin, D. W., Davis, R. L., Gunter, M. J., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1217 · Cited by 95
Analysis of Factors Causing Hyperkalemia
Takaichi, K., Takemoto, F., Ubara, Y., & Mori, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6415 · Cited by 75
Matsumoto, S., Takebayashi, K., & Aso, Y. (2006) · Metabolism · doi:10.1016/j.metabol.2006.07.025 · Cited by 68
Hyperkalemia in diabetes mellitus
Uribarri, J., Oh, M. S., & Carroll, H. J. (1990) · Journal of Diabetes and its Complications · doi:10.1016/0891-6632(90)90057-c · Cited by 62
Püchler, K., Laeis, P., & Stumpe, K. O. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106001-00006 · Cited by 59
Renin-angiotensin blockade and kidney disease
Sarafidis, P. A., & Bakris, G. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61212-x · Cited by 56
Desai, A. S. (2008) · Circulation · doi:10.1161/circulationaha.108.807917 · Cited by 49
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.
Fogari, R., Zoppi, A., Malamani, G. D., Marasi, G., Vanasia, A., & Villa, G. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04482.x · Cited by 45
Izzo, J. L., Weinberg, M. S., Hainer, J. W., Kerkering, J., & Tou, C. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03511.x · Cited by 34
Cited by
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., & Pitt, B. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 669
Self-citationPitt, B., Anker, S. D., Bushinsky, D. A., Kitzman, D. W., Zannad, F., Huang, I.-Z., & on behalf of the PEARL-HF Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq502 · Cited by 438
Chen, D., Li, X., Song, Q., Hu, C., Su, F., Dai, J., Ye, Y., Huang, J., & Zhang, X. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11122 · Cited by 398
Hypokalemia: a clinical update
Kardalas, E., Paschou, S. A., Anagnostis, P., Muscogiuri, G., Siasos, G., & Vryonidou, A. (2018) · Endocrine Connections · doi:10.1530/ec-18-0109 · Cited by 362
Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function
Luo, J., Brunelli, S. M., Jensen, D. E., & Yang, A. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01730215 · Cited by 288
Metadata
- Authors
- Weir, M. R., & Rolfe, M.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2010-03
- Volume
- 5
- Issue
- 3
- Pages
- 531-548
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2157267479
- Cited by
- 265
- References
- 60
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.